Therapeutic enhancement of fracture healing would help to prevent the occurrence of
orthopedic complications such as nonunion and revision surgery. Sclerostin is a negative …

Inhibition of the Wnt antagonist sclerostin increases bone mass in patients with osteoporosis
and in preclinical animal models. Here we show increased levels of the Wnt antagonist …

Type 2 diabetes mellitus results in increased risk of fracture and delayed fracture healing.
ZDF fa/fa rats are an established model of type 2 diabetes mellitus with low bone mass and …

The acetylation polymorphism may affect rates of activation or detoxification of common
carcinogens, thereby influencing cancer risk. Our aim was to define the ethnic distribution of the …

The physiological role of Dickkopf‐1 (Dkk1) during postnatal bone growth in rodents and in
adult rodents was examined utilizing an antibody to Dkk1 (Dkk1‐Ab) that blocked Dkk1 …

Sclerostin (Scl) is an osteocyte protein that decreases bone formation, and its inhibition by
neutralizing antibodies (Scl-Ab) increases bone formation, mass and strength. We …

Polycyclic aromatic hydrocarbons, found in cigarette smoke, food and industrial materials,
are potential human carcinogens. Deficiency of detoxifying enzymes, such as glutathione …

The effects of up to 26 weeks of sclerostin antibody (Scl-Ab) treatment were investigated in
ovariectomized (OVX) rats. Two months after surgery, 6-month-old osteopenic OVX rats were …

Receptor activator of NF‐κB ligand (RANKL) plays a key role in osteoclast‐induced bone
resorption across a range of degenerative bone diseases, and its specific inhibition has been …

In addition to its thoroughly investigated role in bone formation, the osteoblast master
transcription factor RUNX2 also promotes osteoclastogenesis and bone resorption. Here we …